Journal ArticleDOI
Precision Oncology: Who, How, What, When, and When Not?
Lee S. Schwartzberg,Edward S. Kim,David Liu,Deborah Schrag +3 more
- Vol. 37, Iss: 37, pp 160-169
TLDR
Clinicians should be familiar with the types of genomic variants reported by the laboratory and the technology used to determine the results, including limitations of current testing methodologies and reports.Abstract:
Precision oncology, defined as molecular profiling of tumors to identify targetable alterations, is rapidly developing and has entered the mainstream of clinical practice Genomic testing involves many stakeholders working in a coordinated fashion to deliver high-quality tissue samples to high-quality laboratories, where appropriate next-generation sequencing (NGS) molecular analysis leads to actionable results Clinicians should be familiar with the types of genomic variants reported by the laboratory and the technology used to determine the results, including limitations of current testing methodologies and reports Interpretation of genomic results is best undertaken with multidisciplinary input to reduce uncertainty in clinical recommendations relating to a documented variant Non-small cell lung cancer has emerged as a prototype disease where genomic data from at least several well-documented alterations with approved targeted agents are essential for optimal treatment from diagnosis of advanced disease Due to the development of resistance to targeted therapies, resampling and retesting of tumors, including using liquid biopsy technology after clinical progression, may be important in making treatment decisions The value of molecular profiling depends on avoiding both underutilization for well-documented variant target-drug pairs and overutilization of variant-drug therapy without proven benefit As techniques evolve and become more cost effective, the use of molecular testing may prove to add more specificity and improve outcomes for a larger number of patientsread more
Citations
More filters
Journal ArticleDOI
Zebrafish patient avatars in cancer biology and precision cancer therapy.
Maurizio Fazio,Julien Ablain,Julien Ablain,Yan Chuan,David M. Langenau,Leonard I. Zon,Leonard I. Zon +6 more
TL;DR: This Review outlines the recent advances in the creation of both combinatorial transgenic cancer models in zebra fish and zebrafish patient-derived xenograft models, and argues that these models have potential to be used as avatars for precision oncology.
Journal ArticleDOI
The Role of Next-Generation Sequencing in Precision Medicine: A Review of Outcomes in Oncology
TL;DR: The early findings of the impact of next-generation sequencing on cancer patient outcomes are discussed and increased transparency around the determination of “actionable mutations” and a heightened focus on investigating the variations in health insurance coverage across patients receiving sequencing-matched therapies are recommended.
Journal ArticleDOI
When should we order a next generation sequencing test in a patient with cancer
Ramon Colomer,R. Mondejar,Nuria Romero-Laorden,Arantzazu Alfranca,Francisco Sánchez-Madrid,Miguel Quintela-Fandino +5 more
TL;DR: This review will present the status of currently available targeted drugs that can be effective based on actionable molecular alterations, and the NGS tests that are currently available, offering a practical guide for the application of Clinical Precision Oncology in the real world routine practice.
Journal ArticleDOI
Genetic Markers in Lung Cancer Diagnosis: A Review.
TL;DR: It seems that microRNAs and their expression profiles have the greatest diagnostic potential value in lung cancer diagnosis, but their quantification requires standardization.
Journal ArticleDOI
The good, the bad and the autophagosome: exploring unanswered questions of autophagy-dependent cell death
Jurgen Kriel,Ben Loos +1 more
TL;DR: The role of an autophagic flux threshold associated with ‘ lethal’ and ‘non-lethal’ autophagy and its role in autosis control is delineated and cancer treatment avenues will be explored with regards to precision modulation of tumour autophatic flux to ascertain whether autosis induction may present a novel therapeutic strategy.
Related Papers (5)
OncoKB: A Precision Oncology Knowledge Base.
Debyani Chakravarty,Jianjiong Gao,Sarah Fierberg Phillips,Ritika Kundra,Hongxin Zhang,Jiaojiao Wang,Julia E. Rudolph,Rona Yaeger,Tara Soumerai,Moriah H. Nissan,Matthew T. Chang,Sarat Chandarlapaty,Tiffany A. Traina,Paul K. Paik,Alan L. Ho,Feras M. Hantash,Andrew Grupe,Shrujal S. Baxi,Margaret K. Callahan,Alexandra Snyder,Ping Chi,Daniel C. Danila,Mrinal Gounder,James J. Harding,Matthew D. Hellmann,Gopa Iyer,Yelena Y. Janjigian,Thomas Kaley,Douglas A. Levine,Maeve A. Lowery,Antonio M. P. Omuro,Michael A. Postow,Dana Rathkopf,Alexander N. Shoushtari,Neerav Shukla,Martin H. Voss,Ederlinda Paraiso,Ahmet Zehir,Michael F. Berger,Barry S. Taylor,Leonard B. Saltz,Gregory J. Riely,Marc Ladanyi,David M. Hyman,José Baselga,Paul Sabbatini,David B. Solit,Nikolaus Schultz +47 more
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw,Sai-Hong Ignatius Ou,Yung-Jue Bang,D. Ross Camidge,Benjamin Solomon,Ravi Salgia,Gregory J. Riely,Marileila Varella-Garcia,Geoffrey I. Shapiro,Daniel B. Costa,Robert C. Doebele,Long P. Le,Zongli Zheng,Zongli Zheng,Weiwei Tan,Patricia Stephenson,S. Martin Shreeve,L. Tye,James G. Christensen,Keith D. Wilner,Jeffrey W. Clark,A. John Iafrate +21 more